Pegasus Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $987K | Hold |
4,999
| – | – | 0.09% | 62 |
|
|
2024
Q2 | $857K | Sell |
4,999
-100
| -2% | -$16.6K | 0.09% | 66 |
|
|
2024
Q1 | $929K | Buy |
5,099
+89
| +2% | +$15.3K | 0.1% | 67 |
|
|
2023
Q4 | $776K | Sell |
5,010
-137
| -3% | -$20K | 0.09% | 70 |
|
|
2023
Q3 | $767K | Buy |
5,147
+656
| +15% | +$96.3K | 0.11% | 70 |
|
|
2023
Q2 | $605K | Sell |
4,491
-6
| -0.1% | -$880 | 0.09% | 80 |
|
|
2023
Q1 | $717K | Hold |
4,497
| – | – | 0.11% | 69 |
|
|
2022
Q4 | $727K | Hold |
4,497
| – | – | 0.12% | 68 |
|
|
2022
Q3 | $604K | Sell |
4,497
-692
| -13% | -$99.3K | 0.12% | 73 |
|
|
2022
Q2 | $795K | Buy |
5,189
+70
| +1% | +$10.7K | 0.17% | 70 |
|
|
2022
Q1 | $830K | Buy |
5,119
+2,106
| +70% | +$306K | 0.15% | 67 |
|
|
2021
Q4 | $408K | Sell |
3,013
-5,587
| -65% | -$660K | 0.07% | 92 |
|
|
2021
Q3 | $928K | Buy |
8,600
+2
| +0% | +$229 | 0.17% | 60 |
|
|
2021
Q2 | $968K | Buy |
8,598
+3
| +0% | +$338 | 0.19% | 62 |
|
|
2021
Q1 | $930K | Buy |
8,595
+3
| +0% | +$321 | 0.2% | 72 |
|
|
2020
Q4 | $921K | Buy |
8,592
+3
| +0% | +$288 | 0.23% | 84 |
|
|
2020
Q3 | $752K | Buy |
8,589
+3
| +0% | +$282 | 0.23% | 84 |
|
|
2020
Q2 | $843K | Buy |
8,586
+236
| +3% | +$20.8K | 0.27% | 76 |
|
|
2020
Q1 | $636K | Sell |
8,350
-2,854
| -25% | -$243K | 0.25% | 83 |
|
|
2019
Q4 | $992K | Sell |
11,204
-1,549
| -12% | -$129K | 0.3% | 85 |
|
|
2019
Q3 | $966K | Sell |
12,753
-7,838
| -38% | -$537K | 0.33% | 73 |
|
|
2019
Q2 | $1.5M | Sell |
20,591
-2,588
| -11% | -$203K | 0.45% | 63 |
|
|
2019
Q1 | $1.87M | Buy |
23,179
+5,691
| +33% | +$466K | 0.54% | 68 |
|
|
2018
Q4 | $1.61M | Sell |
17,488
-9,459
| -35% | -$832K | 0.48% | 57 |
|
|
2018
Q3 | $2.55M | Buy |
26,947
+271
| +1% | +$25.7K | 0.56% | 61 |
|
|
2018
Q2 | $2.47M | Buy |
26,676
+1,936
| +8% | +$189K | 0.57% | 60 |
|
|
2018
Q1 | $2.34M | Buy |
24,740
+14,690
| +146% | +$1.61M | 0.51% | 58 |
|
|
2017
Q4 | $972K | Buy |
10,050
+307
| +3% | +$28.9K | 0.2% | 118 |
|
|
2017
Q3 | $866K | Sell |
9,743
-157
| -2% | -$12K | 0.2% | 120 |
|
|
2017
Q2 | $718K | Sell |
9,900
-384
| -4% | -$25.8K | 0.19% | 122 |
|
|
2017
Q1 | $670K | Buy |
10,284
+6,300
| +158% | +$396K | 0.28% | 93 |
|
|
2016
Q4 | $249K | Sell |
3,984
-616
| -13% | -$37.6K | 0.11% | 107 |
|
|
2016
Q3 | $290K | Buy |
4,600
+599
| +15% | +$38.8K | 0.14% | 105 |
|
|
2016
Q2 | $248K | Buy |
4,001
+201
| +5% | +$12.2K | 0.13% | 104 |
|
|
2016
Q1 | $217K | Buy |
3,800
+100
| +3% | +$5.57K | 0.12% | 108 |
|
|
2015
Q4 | $219K | Sell |
3,700
-100
| -3% | -$5.76K | 0.11% | 89 |
|
|
2015
Q3 | $207K | Sell |
3,800
-3,300
| -46% | -$215K | 0.12% | 81 |
|
|
2015
Q2 | $477K | Buy |
+7,100
| New | +$464K | 0.21% | 64 |
|
Other funds holding ABBV
Pegasus Partners's ABBV Position: Q3 2024 in Review
Pegasus Partners held its AbbVie (ABBV) position steady in Q3 2024 at 4,999 shares worth $987K. The position accounts for 0.09% of the portfolio, ranked #62.
Pegasus Partners first reported a position in ABBV in Q2 2015 and has held it in 38 quarters since. The position peaked at $2.55M in Q3 2018. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.
- Pegasus Partners held 4,999 shares of AbbVie worth $987K as of Q3 2024.
- Pegasus Partners left its AbbVie share count unchanged in Q3 2024.
- AbbVie made up 0.09% of Pegasus Partners's portfolio in Q3 2024, its #62 holding.
- Pegasus Partners first reported a position in AbbVie in Q2 2015 and has held it in 38 quarters since.
- Pegasus Partners's AbbVie position peaked at $2.55M in Q3 2018.
- 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.
Based on Pegasus Partners's 13F filing for Q3 2024, filed 1 Nov 2024.